Dr Mehdi Touat
- Specialty
- Neuro-oncologist, expert in primary brain tumors in adults
- Hospital
- Hôpital Pitié Salpétrière (Paris), APHP, Sorbonne Université, Institut du Cerveau
- Latest articles
-
- 18F-DOPA-PET and advanced MRI improve treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitors. (Feb 2, 2026)
- RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastoma. (Jan 8, 2026)
- Dramatic response to entrectinib in a rare glioneuronal tumor harboring an NTRK2 fusion. (Dec 27, 2025)
- Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial. (Dec 1, 2025)
- Author Correction: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas. (Oct 9, 2025)